Biophage Pharma Announces The Launch Of Its Roadshows
11:47 EST Monday, January 08, 2007
MONTREAL, Jan. 8 /CNW Telbec/ - (TSX-V: BUG) Biophage Pharma Inc. ("Biophage") is pleased to announce its 2007 roadshow plans for several major cities in Canada and the United States, beginning in Quebec City on January 9th. The purpose of the event is to increase the visibility of the Corporation by focusing on accomplishments of the past few months at both the corporate level and in product development.
Renmark Financial Communications Inc., with an ongoing mandate to provide comprehensive investor and financial communications services, will coordinate the events, focusing their assets and extensive expertise in networking and investor relations to market Biophage during the roadshows.
Biophage also announces that it's President and CEO is featured in an online interview at Wallst.net, a Financial Media Group Inc. company (wallst.net) and for this week only at the Wall Street Reporter Magazine, international section (www.wallstreetreporter.com).
"As a result of many recent developments at Biophage, it is an opportune time to increase our exposure on the North American markets. While the roadshow events are aimed at meeting our existing retail brokers and portfolio managers, Biophage would like to extend an open invitation to all other brokers and members of the financial community who may be interested in the Biophage business model. In order to know the exact dates and times and to register, please consult our web site (special events). Also, should any company or individual want to know more about our products, services and our Research and Technology developments, they are welcomed to visit our new websites (www.biophagepharma.com and www.immunotoxlabs.com or to contact us directly." commented Dr. Mandeville, President and CEO of Biophage Pharma.
About Biophage Pharma Inc.
Biophage Pharma is a high potential, revenue-driven Canadian biotechnology company focused on the development of innovative phage-based products and technologies for the detection and management of bacterial contaminations. Founded in 1995, Biophage operates three divisions: (1) The Therapeutic division for the management of bacterial contaminations in the medical, veterinary and environmental fields; (2) The Biosensors division for the development and commercialization of new diagnostic products, more particularly a compact PDS96(R) Biosensor which is entering in the pre-commercialization stage; (3) The Immunotox Labs division, which provides services in Immunogenicity and Immunotoxicity, Nanotoxicity and Ecotoxicology, Beryllium sensitivity testing and MELISA(R) testing for the detection of sensitization to more than 200 different allergens including metals, penicillin, gluten and pollens. (www.biophagepharma.net ; www.immunotoxlabs.com).
About Renmark Financial Communications Inc.
Founded in 1999, Renmark Financial Communications Inc. is a full service investor relations firm, specializing in corporate financial communications and investor relations to small, mid and large cap companies listed on all US and Canadian exchanges in North America. Established as one of the largest retail Investor Relations firms in Canada, Renmark offers a wide range of integrated investor and financial communication services. An expert team of 30 experienced and strong professionals, with a combined experience of over 100 years, is dedicated to provide efficient and comprehensive investor relations program. The constant strive for excellence has given, and will continue to give Renmark the edge needed to become North America's leading investor relations and corporate communications firm. www.renmarkfinancial.com
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.
%SEDAR: 00014714EF
For further information: Biophage Pharma Inc.: Rosemonde Mandeville, M.B., Ch.B., PhD., President and Chief Executive Officer, (514) 496-1488, rosemonde.mandeville@biophagepharma.net; Renmark Financial Communications Inc.: Christine Stewart, cstewart@renmarkfinancial.com; Sylvain Laberge, slaberge@renmarkfinancial.com; (514) 939-3989, Fax : (514) 939-3717, www.renmarkfinancial.com
